Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M286,069Revenue $M71,312Net Margin (%)22.0Z-Score0
Enterprise Value $M286,069EPS $4.8Operating Margin %28.2F-Score0
P/E(ttm))17.9Cash Flow Per Share $6.2Pre-tax Margin (%)27.7Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %3.2Quick Ratio0Cash flow > EarningsN
Price/Sales3.95-y EBITDA Growth Rate %3.0Current Ratio0Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %4.9ROA % (ttm)14.8Higher Current Ratio y-yN
Dividend Yield %2.7Insider Buy (3m)0ROE % (ttm)26.1Less Shares Outstanding y-yN
Payout Ratio %45.0Shares Outstanding M2,799ROI % (ttm)15.4Gross Margin Increase y-yN

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJJoel Greenblatt 2014-09-30 Buy 0.02%$99.82 - $108.64
($103.64)
$ 102.2-1%New holding, 14319 sh.14,319
JNJRay Dalio 2014-09-30 Add0.02%$99.82 - $108.64
($103.64)
$ 102.2-1%Add 27.77%84,193
JNJDodge & Cox 2014-09-30 Add$99.82 - $108.64
($103.64)
$ 102.2-1%Add 21.93%47,095
JNJHOTCHKIS & WILEY 2014-09-30 Reduce-0.53%$99.82 - $108.64
($103.64)
$ 102.2-1%Reduce -99.8%2,862
JNJJames Barrow 2014-09-30 Reduce-0.24%$99.82 - $108.64
($103.64)
$ 102.2-1%Reduce -10.05%15,350,650
JNJYacktman Focused Fund 2014-09-30 Reduce-0.21%$99.82 - $108.64
($103.64)
$ 102.2-1%Reduce -6.06%3,100,000
JNJDonald Yacktman 2014-09-30 Reduce-0.17%$99.82 - $108.64
($103.64)
$ 102.2-1%Reduce -4.36%8,651,258
JNJYacktman Fund 2014-09-30 Reduce-0.13%$99.82 - $108.64
($103.64)
$ 102.2-1%Reduce -3.7%3,900,000
JNJGeorge Soros 2014-09-30 Sold Out -0.04%$99.82 - $108.64
($103.64)
$ 102.2-1%Sold Out0
JNJJohn Rogers 2014-06-30 Add0.2%$96.54 - $105.76
($101.02)
$ 102.21%Add 42.46%522,727
JNJRichard Pzena 2014-06-30 Add0.17%$96.54 - $105.76
($101.02)
$ 102.21%Add 33.12%1,155,666
JNJHOTCHKIS & WILEY 2014-06-30 Reduce-0.89%$96.54 - $105.76
($101.02)
$ 102.21%Reduce -63.73%1,426,614
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 102.21%Reduce -13.16%3,300,000
JNJRobert Olstein 2014-06-30 Reduce-0.31%$96.54 - $105.76
($101.02)
$ 102.21%Reduce -20.91%87,000
JNJDonald Yacktman 2014-06-30 Reduce-0.21%$96.54 - $105.76
($101.02)
$ 102.21%Reduce -5.5%9,045,902
JNJTweedy Browne 2014-06-30 Reduce-0.17%$96.54 - $105.76
($101.02)
$ 102.21%Reduce -1.71%4,196,224
JNJRay Dalio 2014-06-30 Reduce-0.16%$96.54 - $105.76
($101.02)
$ 102.21%Reduce -74.94%65,893
JNJGeorge Soros 2014-06-30 Reduce-0.05%$96.54 - $105.76
($101.02)
$ 102.21%Reduce -51.22%50,000
JNJJoel Greenblatt 2014-06-30 Sold Out -0.01%$96.54 - $105.76
($101.02)
$ 102.21%Sold Out0
JNJJohn Hussman 2014-06-30 Reduce-0.01%$96.54 - $105.76
($101.02)
$ 102.21%Reduce -50%1,325
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ Brian Rogers 2014-12-314,633,0000.171.7
JNJ Yacktman Focused Fund 2014-12-313,100,0000.113.5
JNJ Yacktman Fund 2014-12-313,900,0000.143.5
JNJ Joel Greenblatt 2014-09-3014,31900.02New Buy
JNJ Ray Dalio 2014-09-3084,19300.07+27.77%
JNJ Dodge & Cox 2014-09-3047,09500+21.93%
JNJ John Rogers 2014-09-30536,6160.020.74+2.66%
JNJ Richard Pzena 2014-09-301,184,4160.040.69+2.49%
JNJ Jean-Marie Eveillard 2014-09-301,651,6220.060.44+1.73%
JNJ Richard Snow 2014-09-303,27000.01+0.77%
JNJ Ruane Cunniff 2014-09-3076,25900.04+0.32%
JNJ Richard Perry 2014-09-30342,2770.011.3
JNJ John Hussman 2014-09-301,32500.01
JNJ Warren Buffett 2014-09-30327,1000.010.03
JNJ Michael Price 2014-09-3035,00000.47
JNJ Tom Gayner 2014-09-30574,2000.021.7
JNJ Ken Fisher 2014-09-3010,446,1560.372.4-0.02%
JNJ PRIMECAP Management 2014-09-3012,217,8130.441.4-0.2%
JNJ Tweedy Browne 2014-09-304,163,9340.1510.2-0.77%
JNJ Mario Gabelli 2014-09-30366,3660.010.21-1.83%
JNJ Prem Watsa 2014-09-3082,85000.6-2.18%
JNJ Donald Yacktman 2014-09-308,651,2580.313.8-4.36%
JNJ Robert Olstein 2014-09-3083,00001.2-4.6%
JNJ James Barrow 2014-09-3015,350,6500.552.2-10.05%
JNJ HOTCHKIS & WILEY 2014-09-302,86200-99.8%
JNJ George Soros 2014-09-30000Sold Out
JNJ Mark Hillman 2013-12-3130,74604.2-0.27%
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
JOHNSON & JOHNSON10% Owner 2014-12-17Sell8,100$7.621241.21view
JOHNSON & JOHNSON10% Owner 2014-12-12Sell5,000$7.511260.85view
JOHNSON & JOHNSON10% Owner 2014-12-10Sell8,300$7.721223.83view
JOHNSON & JOHNSON10% Owner 2014-12-05Sell15,900$7.761217.01view
JOHNSON & JOHNSON10% Owner 2014-12-01Sell1,200$7.541255.44view
JOHNSON & JOHNSON10% Owner 2014-11-26Sell2,000$7.751218.71view
JOHNSON & JOHNSON10% Owner 2014-11-24Sell9,500$8.141155.53view
JOHNSON & JOHNSON10% Owner 2014-11-12Buy40,000$18467.78view
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-5.85view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-4.87view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
    Johnson & Johnson's Strong Momentum Will Continue Jan 22 2015 
    Johnson and Johnson Beats Earnings Estimate, Slides On a Weak Outlook Jan 21 2015 
    Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
    9 High Rated, Lower Debt Dividend Stocks With A Reasonable Payout Jan 13 2015 
    Dividend Smart Stocks Jan 12 2015 
    What's Your Retirement Vision? Dec 30 2014 
    NASDAQ Dividend Achievers: Deere & Company Dec 19 2014 
    Is Johnson & Johnson Still A Worthy Buy? Dec 18 2014 
    Why I Sold American Realty Capital Properties Dec 17 2014 


    More From Other Websites
    Business Highlights Jan 23 2015
    Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog Jan 23 2015
    Stocks mostly fall, curbing first weekly advance in 4 Jan 23 2015
    Dow 30 Stock Roundup: AmEx, UnitedHealth Beat, IBM Earnings Fall Y/Y - Analyst Blog Jan 23 2015
    Three More FIFA Sponsors Won’t Renew With Soccer Authority Jan 23 2015
    First GSK Ebola vaccine shipment due to arrive in Liberia Jan 23 2015
    J&J’s Foes Say Phone Solicitations Didn’t Taint Mesh Suits Jan 22 2015
    Cramer: Domestic's working Jan 22 2015
    Cramer: Avoid stocks getting crushed by this Jan 22 2015
    Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Jan 22 2015
    This is what a currency war looks like Jan 22 2015
    Natus Medical's a Strong Buy on Expanding Product Portfolio - Analyst Blog Jan 22 2015
    Judge to decide if Boston Scientific should pay $7.2B to Johnson & Johnson Jan 22 2015
    Morgan Stanley Analyst Sees FY15 'Trough' For Johnson & Johnson Pharma Growth Jan 22 2015
    Covidien Q1 Earnings Beat Estimates As Buyout Nears Jan 22 2015
    Cramer: US rates all over map Jan 22 2015
    MBA Students: Choose Your First Marketing Job Wisely Jan 22 2015
    J&J Seeks Billions in Trial Over Decade-Old Bidding War Jan 21 2015
    J&J's $7.2 bln claim against Boston Scientific now with U.S. judge Jan 21 2015
    Bayer Announces Updates to European Label of Xarelto - Analyst Blog Jan 21 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK